TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39160109

Group type: EXPERIMENTAL
Intervention: Kenyan national diarrheal policy frameworks, plans, strategies, laws, institutional frameworks and operational guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Policies for advocacy, health communication, social mobilisation, logistics management, and prevention strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapid diagnosis, vaccine development and deployment, and strong funding commitment
Number of subjects: 0
Study: 39160110

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy (HFNO)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 500
Study: 39160146

Group type: EXPERIMENTAL
Intervention: Bimodal treatment (sound therapy + electrical tongue stimulation)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Sound-only stimulation
Number of subjects: 112
Study: 39160255

Group type: EXPERIMENTAL
Intervention: High-risk expression subtype at progression
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Immunotherapy targets
Number of subjects: 1143
Study: 39160351

Group type: EXPERIMENTAL
Intervention: Adaptive deep brain stimulation (DBS)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Continuous deep brain stimulation (DBS)
Number of subjects: 4
Study: 39160459

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily for at least 8 weeks, followed by 5 or 10 mg twice daily at investigator's discretion
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 110
Study: 39160468

Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich fraction (TRF) vitamin E, 50 mg daily for six months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 39160528

Group type: EXPERIMENTAL
Intervention: COVID-19 infection
Number of subjects: 388

Group type: COMPARATOR
Intervention: Matched comparators without COVID-19
Number of subjects: 388
Study: 39160566

Group type: EXPERIMENTAL
Intervention: REACH, a web-based social learning and cognitive behavior therapy (SLCBT) intervention
Number of subjects: 460

Group type: COMPARATOR
Intervention: Educational web-based safety comparison condition (EC)
Number of subjects: 460
Study: 39160612

Group type: EXPERIMENTAL
Intervention: Air purifiers used in homes, reported running virtually 24 hours every day, with approximately 80% on medium setting.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Air purifiers used in homes, with structured interviews conducted with a subset of 26 participants.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Air purifiers used in homes, tolerance to noise measured at 30-day and 90-day visits.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Electricity consumption recorded using HOBO monitors from a subset of 45 participants.
Number of subjects: 150
Study: 39160614

Group type: EXPERIMENTAL
Intervention: Nudges to patients and/or clinicians
Number of subjects: 0

Group type: COMPARATOR
Intervention: No nudges (control group)
Number of subjects: 0
Study: 39160651

Group type: EXPERIMENTAL
Intervention: Brepocitinib
Number of subjects: 0
Study: 39160668

Group type: EXPERIMENTAL
Intervention: Ceramic liner
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polyethylene liner
Number of subjects: 0
Study: 39160756

Group type: EXPERIMENTAL
Intervention: +EAA
Number of subjects: 17

Group type: COMPARATOR
Intervention: +CHO
Number of subjects: 17
Study: 39161224

Group type: EXPERIMENTAL
Intervention: Levcromakalim
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study: 39161543

Group type: EXPERIMENTAL
Intervention: Lenalidomide 20 mg with intravenous obinutuzumab 1000 mg
Number of subjects: 66
Study: 39161559

Group type: EXPERIMENTAL
Intervention: Gamified, fully immersive and stroke-specific virtual reality intervention for 10 weeks starting at week 3 poststroke
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 94
Study: 39161801

Group type: EXPERIMENTAL
Intervention: blinded i.v. iron (1000 mg ferric derisomaltose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 39161865

Group type: EXPERIMENTAL
Intervention: Sexual counseling training based on the PLISSIT model (3 sessions)
Number of subjects: 74

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sexual counseling training based on the PLISSIT model
Number of subjects: 74
Study: 39161870

Group type: EXPERIMENTAL
Intervention: Strict bundled care treatment (BCT) over the first 72 hours during acute hospital care
Number of subjects: 681

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 681
Study: 39161962

Group type: EXPERIMENTAL
Intervention: Varlilumab followed by Atezolizumab with palliative radiation therapy (RT)
Number of subjects: 15
Study: 39162035

Group type: EXPERIMENTAL
Intervention: Ketone Ester (KE) treatment (25 g D-ß-hydroxybutyrate-(R)-1,3-butanediol × 4 daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketone Ester (KE) treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 39162209

Group type: EXPERIMENTAL
Intervention: SPY fluorescence angiography
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control (historic cohort without SPY)
Number of subjects: 332
Study: 39162220

Group type: EXPERIMENTAL
Intervention: Tranexamic acid; specific dosage and duration not mentioned
Number of subjects: 0
Study: 39162334

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 206
Study: 39162385

Group type: EXPERIMENTAL
Intervention: Hypothermic compression bandage
Number of subjects: 310

Group type: COMPARATOR
Intervention: Conventional compression bandage
Number of subjects: 310
Study: 39162632

Group type: EXPERIMENTAL
Intervention: CCTA plus CT-FFR
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CCTA plus CT perfusion
Number of subjects: 105

Group type: COMPARATOR
Intervention: CCTA alone
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Sequential CCTA plus CT-FFR and CT perfusion
Number of subjects: 105
Study: 39162633

Group type: EXPERIMENTAL
Intervention: Shear-wave dispersion slope (DS)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Attenuation coefficient (AC)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Shear-wave speed (SWS)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Multiparametric US imaging markers
Number of subjects: 124
Study: 39162634

Group type: EXPERIMENTAL
Intervention: Lutetium 177 (specific dosage and duration not mentioned)
Number of subjects: 0
Study: 39162825

Group type: EXPERIMENTAL
Intervention: NPi ≤ 2
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: qPLR < 4%
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Combined qPLR < 4% and NPi ≤ 2 with NSE > 60 μg/L
Number of subjects: 710
Study: 39162872

Group type: EXPERIMENTAL
Intervention: Nivolumab + chemotherapy (SOX or CAPOX)
Number of subjects: 717

Group type: COMPARATOR
Intervention: Placebo + chemotherapy (SOX or CAPOX)
Number of subjects: 717
Study: 39162882

Group type: EXPERIMENTAL
Intervention: Prone positioning (PP) during venovenous extracorporeal membrane oxygenation (VV-ECMO)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Supine positioning during venovenous extracorporeal membrane oxygenation (VV-ECMO)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Prone positioning (PP) during VV-ECMO
Number of subjects: 165
Study: 39162912

Group type: EXPERIMENTAL
Intervention: tDCS (transcranial direct current stimulation) provided in bilateral frontal montage, F3 anode, F4 cathode, 2 mA, for 30 min, in a 6-week trial, for total 21 sessions
Number of subjects: 44
Study: 39163044

Group type: EXPERIMENTAL
Intervention: Maya mobile app-based cognitive behavioral therapy (CBT) intervention for 6 weeks with text message-based incentives (gain-framed, loss-framed, gain-social support)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Maya mobile app-based cognitive behavioral therapy (CBT) intervention
Number of subjects: 59
Study: 39163043

Group type: EXPERIMENTAL
Intervention: Clean Cut multimodal surgical quality improvement program
Number of subjects: 9755

Group type: COMPARATOR
Intervention: Control period (before implementation of the intervention)
Number of subjects: 9755

Group type: EXPERIMENTAL
Intervention: High compliance with perioperative standards (regardless of trial arm)
Number of subjects: 9755
Study: 39163327

Group type: EXPERIMENTAL
Intervention: 3 days of face-down positioning (FDP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7 days of face-down positioning (FDP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 days of FDP
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7 days of FDP
Number of subjects: 0
Study: 39163362

Group type: EXPERIMENTAL
Intervention: CRP-guided treatment
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: PCT-guided treatment
Number of subjects: 468

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 468
Study: 39163371

Group type: EXPERIMENTAL
Intervention: PCSK9 levels measured at 48 hours after PCI
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: PCSK9 levels measured at 24 hours after PCI
Number of subjects: 205
Study: 39163415

Group type: EXPERIMENTAL
Intervention: Deprescribing tools and approaches in palliative oncology care
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Qualitative phase with semi-structured interviews
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Quantitative study with self-questionnaires (BMQ and rPATD)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Auxiliary study assessing health literacy
Number of subjects: 300
Study: 39163505

Group type: EXPERIMENTAL
Intervention: Apalutamide plus androgen deprivation therapy (ADT)
Number of subjects: 2259

Group type: EXPERIMENTAL
Intervention: Apalutamide plus ADT
Number of subjects: 2259

Group type: COMPARATOR
Intervention: Placebo plus ADT
Number of subjects: 2259
Study: 39163589

Group type: EXPERIMENTAL
Intervention: Real-Time Feedback (RTF) supported home exercise
Number of subjects: 70

Group type: COMPARATOR
Intervention: Paper instructions for exercise guidance
Number of subjects: 70
Study: 39163591

Group type: EXPERIMENTAL
Intervention: uTECH+YMHP (SMS text messages informed by ML algorithm + YMHP counseling)
Number of subjects: 330

Group type: COMPARATOR
Intervention: YMHP (4 motivational interviewing-based counseling sessions)
Number of subjects: 330
Study: 39163592

Group type: EXPERIMENTAL
Intervention: CT-152 (smartphone app-based digital therapeutic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham DTx (digital working memory exercise with emotionally neutral stimuli)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT-152
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham DTx
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT-152 and Sham DTx
Number of subjects: 0
Study: 39163699

Group type: EXPERIMENTAL
Intervention: Intraoperative mean cerebrospinal fluid pressure (CSFP)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cardiac-driven CSFP peak-to-valley amplitude (CSFPp)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CSFP during extubation
Number of subjects: 21
Study: 39163858

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) 4 g
Number of subjects: 309

Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 309
Study: 39163971

Group type: EXPERIMENTAL
Intervention: Maple syrup
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sucrose syrup
Number of subjects: 42
Study: 39163972

Group type: EXPERIMENTAL
Intervention: Total polyphenol intake (∼914 mg/1000 kcal/d)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Prenol lipids
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Phenylpropanoic acids
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Cinnamic acids and derivatives
Number of subjects: 350
Study: 39163973

Group type: EXPERIMENTAL
Intervention: Whole wheat bread
Number of subjects: 5
Study: 39163976

Group type: EXPERIMENTAL
Intervention: LC → LF diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: UPF → MPF diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: MPF → UPF diet
Number of subjects: 20
Study: 39164041

Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery followed by platinum-based chemotherapy plus or minus bevacizumab
Number of subjects: 124

Group type: COMPARATOR
Intervention: Platinum-based chemotherapy plus or minus bevacizumab alone
Number of subjects: 124
Study: 39164062

Group type: EXPERIMENTAL
Intervention: Active care
Number of subjects: 242

Group type: COMPARATOR
Intervention: Comfort care
Number of subjects: 242

Group type: COMPARATOR
Intervention: Other
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Prenatal consult
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Primary decision-maker
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Infant alive at survey completion
Number of subjects: 242
Study: 39164067

Group type: EXPERIMENTAL
Intervention: apremilast 30 mg two times per day
Number of subjects: 308

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 308
Study: 39164167

Group type: EXPERIMENTAL
Intervention: Serum mid-infrared spectroscopy (MIRS)
Number of subjects: 108
Study: 39164233

Group type: EXPERIMENTAL
Intervention: Platelet Reactivity ExpreSsion Score (PRESS) with hyperreactive platelet response (>60% aggregation) to 0.4 µM epinephrine
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PRESS score above the median
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PRESS (cross-validation)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PRESS (validation in healthy participants)
Number of subjects: 129
Study: 39164407

Group type: EXPERIMENTAL
Intervention: Bosutinib (starting dose: 500 mg QD)
Number of subjects: 163
Study: 39164518

Group type: EXPERIMENTAL
Intervention: Androgen receptor pathway inhibitors (ARPIs)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Taxanes
Number of subjects: 218

Group type: COMPARATOR
Intervention: Physician's choice
Number of subjects: 218
Study: 39164557

Group type: EXPERIMENTAL
Intervention: Adjunct opicapone 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levodopa 100 mg
Number of subjects: 0
Study: 39164613

Group type: EXPERIMENTAL
Intervention: Transforaminal epidural injections (TEI)
Number of subjects: 388
Study: 39164634

Group type: EXPERIMENTAL
Intervention: Primary Care Behavioral Health (PCBH) model implemented in 24 primary care centres
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard care in 48 primary care centres
Number of subjects: 72
Study: 39164673

Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal conjugate vaccine (PCV10)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (children without pneumonia)
Number of subjects: 1000
Study: 39164727

Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Formula feeding (FF)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Educational intervention to promote breastfeeding, nutrition, and sustainability
Number of subjects: 408
Study: 39164770

Group type: EXPERIMENTAL
Intervention: Brief Alcohol Intervention (BAI)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 564
Study: 39164808

Group type: EXPERIMENTAL
Intervention: 7-day vonoprazan-based triple therapy with high-dose amoxicillin (VAC-7)
Number of subjects: 628

Group type: COMPARATOR
Intervention: 14-day extended sequential therapy (S-14)
Number of subjects: 628
Study: 39164924

Group type: EXPERIMENTAL
Intervention: Pembrolizumab added to standard of care chemoradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care chemoradiation
Number of subjects: 0
Study: 39164933

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) - 25 weekly sessions including behavioural activation, behaviour management, interventions for the caregiver, reminiscence, couples counselling, and cognitive restructuring
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 41
Study: 39165152

Group type: EXPERIMENTAL
Intervention: Cryo-pneumatic compression
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care (including standard cryotherapy)
Number of subjects: 200
Study: 39165177

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 127

Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 127
Study: 39165278

Group type: EXPERIMENTAL
Intervention: hAECs transplantation (hAECT)
Number of subjects: 35
Study: 39165373

Group type: EXPERIMENTAL
Intervention: Evening LAMA administration
Number of subjects: 10013

Group type: COMPARATOR
Intervention: Morning LAMA administration
Number of subjects: 10013
Study: 39165398

Group type: EXPERIMENTAL
Intervention: Newly diagnosed axSpA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient self-reported assessments
Number of subjects: 0
Study: 39165487

Group type: EXPERIMENTAL
Intervention: Postoperative NEC (Bell's stage ≥2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No postoperative NEC
Number of subjects: 0
Study: 39165498

Group type: EXPERIMENTAL
Intervention: cfDNA methylation-based lung cancer screening model
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: protein model
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: mutation model
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: final screening model (cfDNA methylation and protein features)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: multi-omics screening model
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: AI-aided pulmonary nodules diagnostic model (cfDNA methylation and CT images features)
Number of subjects: 465
Study: 39165810

Group type: EXPERIMENTAL
Intervention: Bacterial coinfections present during hospitalization for COVID-19 variants (Alpha, Delta, Omicron)
Number of subjects: 21186

Group type: EXPERIMENTAL
Intervention: Delta variant with bacterial coinfections
Number of subjects: 21186

Group type: EXPERIMENTAL
Intervention: All variants with bacterial coinfections
Number of subjects: 21186

Group type: EXPERIMENTAL
Intervention: Delta variant
Number of subjects: 21186
Study: 39166323

Group type: EXPERIMENTAL
Intervention: Sedentary behavior reduction intervention
Number of subjects: 271

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 271
Study: 39166322

Group type: EXPERIMENTAL
Intervention: Virtual Diabetes Care Model with Continuous Glucose Monitoring
Number of subjects: 0
Study: 39166327

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg once daily)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 39166332

Group type: EXPERIMENTAL
Intervention: Guideline-Based Telemedicine Assessment by General Practitioners
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-Face Consultations with Specialists
Number of subjects: 0
Study: 39166425

Group type: COMPARATOR
Intervention: SHR-2004 (0.1, 0.3, or 1.0 mg/kg) administered intravenously (i.v.)
Number of subjects: 64

Group type: COMPARATOR
Intervention: SHR-2004 (0.5, 1.0, 3.0, or 4.5 mg/kg) administered subcutaneously (s.c.)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 39166465

Group type: EXPERIMENTAL
Intervention: Immunosuppression withdrawal (ISW) at a median of 7.4 weeks before graft hysterectomy (Hx)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Graft hysterectomy (Hx)
Number of subjects: 6
Study: 39166663

Group type: EXPERIMENTAL
Intervention: Compression stockings
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo stockings
Number of subjects: 63
Study: 39166750

Group type: EXPERIMENTAL
Intervention: Higher hepatic glucose production (HGP-insulin)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Lower % suppression of HGP
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: HGP-basal, M-low, and M-high
Number of subjects: 450
Study: 39166791

Group type: EXPERIMENTAL
Intervention: CT1812
Number of subjects: 0
Study: 39167110

Group type: EXPERIMENTAL
Intervention: Postoperative orthosis (CO) for 6 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: No orthosis (NO)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Postoperative orthosis (CO)
Number of subjects: 62
Study: 39167148

Group type: EXPERIMENTAL
Intervention: 100 mg tablet of selvigaltin under fasted conditions
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 100 mg tablet of selvigaltin under fed conditions
Number of subjects: 13

Group type: COMPARATOR
Intervention: 50 mg capsule of selvigaltin under fasted conditions
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: All treatments of selvigaltin (tablet and capsule)
Number of subjects: 13
Study: 39167241

Group type: EXPERIMENTAL
Intervention: SOFA score, SpO2, and respiratory effort signals
Number of subjects: 346

Group type: COMPARATOR
Intervention: ROX index
Number of subjects: 346
Study: 39167305

Group type: EXPERIMENTAL
Intervention: Absorbable gelatin sponge (AGS)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel with AGS
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Tranexamic acid with AGS
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 98
Study: 39167348

Group type: EXPERIMENTAL
Intervention: Venetoclax treatment
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Venetoclax treatment with concomitant rituximab
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Venetoclax treatment with 1 prior line of therapy
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Venetoclax treatment with ≥ 2 prior lines of therapy
Number of subjects: 129
Study: 39167366

Group type: EXPERIMENTAL
Intervention: Zasocitinib 2 mg
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Zasocitinib 5 mg
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Zasocitinib 15 mg
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Zasocitinib 30 mg
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Zasocitinib (all doses)
Number of subjects: 259
Study: 39167421

Group type: EXPERIMENTAL
Intervention: CBD (300 mg) and terpenes (1 mg each of linalool, myrcene, phytol, limonene, α-terpinene, α-terpineol, α-pinene, and β-caryophyllene)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 39167443

Group type: EXPERIMENTAL
Intervention: Inspired video game intervention
Number of subjects: 48